MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
common stock
$1,600K
Net cash provided by
financing activities
$1,600K
Net (decrease) in
cash, cash...
-$8,762K
Canceled cashflow
$1,600K
Change in fair value of
contingent consideration
$1,553K
Accounts receivable
-$1,342K
Depreciation and
amortization
$242K
Amortization of right-of-use
asset
$218K
Other noncurrent
assets
-$198K
Accounts payable
$177K
Loss on
disposal/sale of subsidiary
-$98K
Loss from sale of
property and equipment
-$90K
Prepaid expenses and
other current assets
-$39K
Equity-based compensation
$2K
Proceeds from sale of
subsidiary
$474K
Proceeds from sale of
fixed assets
$42K
Net cash used in
operating activities
-$8,555K
Net cash used in by
investing activities
-$1,807K
Canceled cashflow
$3,959K
Canceled cashflow
$516K
Gain on early lease
termination
$5,974K
Net loss
-$4,946K
Acquisition of gpcr
therapeutics usa inc
$2,090K
Income tax benefit
-$634K
Accrued expenses
-$614K
Gain on settlement of
accounts payables
$346K
Cash removed from the
sale of kcc
$232K
Capital expenditures
$1K
Back
Back
Cash Flow
EXICURE, INC. (XCUR)
EXICURE, INC. (XCUR)
source: myfinsight.com